Affimed N.V. (0HL9.L)
Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States and Germany.
$0.00+0.00%
StockGlow Score
Bearish
BearishBullish
1 year ago+0.0%
The outlook
Affimed N.V. currently reads as bearish based on below its 50- & 200-day averages, 0% of the way from its 52-week low to high. This is a snapshot of current market data, not a forecast.
What’s behind the score
Price trendBelow its 50- & 200-day averages
52-week range0% of the way from its 52-week low to high
Market cap
—
52-wk high
$10.91
52-wk low
$0.00
50-day avg
$5.51
200-day avg
$5.86
Trailing P/E
—